Those safeguards have now been shaken by the revelation that one prolific donor, used nearly 200 times worldwide, carried a rare genetic mutation associated with serious childhood cancers.
A donor known only as “Kjeld”
Denmark has become a powerhouse in the fertility industry, home to one of the largest sperm banks on the planet: the European Sperm Bank. Its samples are shipped across continents and used in dozens of clinics each year.
Between 2006 and 2022, one anonymous Danish donor, registered under the pseudonym “Kjeld”, became one of its most in-demand profiles. His sperm was exported to 67 clinics in 14 different countries.
According to Danish public broadcaster DR, those vials of sperm led to the birth of 197 children around the world, including 99 in Denmark alone. For many couples and single parents facing infertility, he was the stepping stone to a long‑awaited pregnancy.
From a single donor, nearly 200 children were conceived over 16 years before a hidden genetic risk was detected.
The case has now turned from a story of medical success into a serious ethical and regulatory debate, after several of the donor’s offspring were diagnosed with cancer at a very young age.
How the alarm was raised
The first sign that something was wrong came in April 2020. The sperm bank was notified that a child conceived with “Kjeld’s” sperm had developed cancer, and doctors had identified an underlying genetic anomaly.
At that stage, it was still a single case. Fertility centres deal with huge numbers of births, and sporadic illnesses can occur for unrelated reasons. The sperm bank did not yet have proof of a pattern.
Three years later, another report reached the institution: a second child, also conceived from the same donor, had a similar diagnosis and the same type of mutation. This second alert was the tipping point.
➡️ This is the best way to reheat leftovers so they actually taste fresh again
➡️ Psychology explains why emotional exhaustion can appear without obvious stress
➡️ The genius trick to stop eggs sticking to the pan without butter or water
➡️ Researchers uncover promising stem cells that could regenerate teeth and bone
➡️ He films his stalker on camera: kayaker narrowly escapes great white shark off California
➡️ While He Thought He’d Struck Gold, An Australian Was Holding A Fragment Of The Solar System
➡️ Geologists find mysterious tunnels in stone that hint at a lifeform never seen on Earth
The bank halted further use of the donor’s samples and initiated a detailed genetic analysis of the stored sperm. That investigation revealed something that had slipped through routine screening: a rare mutation affecting the TP53 gene.
The mutation had not been picked up during initial donor screening, despite being linked to increased cancer risk.
What is TP53 and why does it matter?
The TP53 gene is one of the most closely watched in cancer research. It provides instructions for making a protein, p53, often nicknamed the “guardian of the genome”.
This protein plays a crucial quality‑control role inside cells. It checks DNA for damage, pauses cell division when errors occur, and either helps repair that DNA or triggers cell death if the damage is beyond repair.
When TP53 is working properly:
- damaged cells are stopped from dividing
- mutations are less likely to accumulate
- the risk of tumours forming is reduced
A mutation in TP53 can disable or weaken this defence system. Cells can start to multiply despite carrying serious DNA errors, which can lead to the development of cancer, including aggressive childhood cancers.
A rare and unusual mutation
In this Danish case, the sperm bank reported that the donor did not have a typical, inherited TP53 mutation in all his cells. Instead, he carried a rare and previously undescribed variant that appeared only in a fraction of his sperm cells.
The donor himself showed no signs of disease, because the mutation was confined to part of his sperm and not present across his whole body.
This situation points to what geneticists call mosaicism: a person carries a mutation in some cells but not others. Standard medical tests, often based on blood samples, can miss such mosaic mutations if they are absent from the tissues being analysed.
Not every child conceived with this donor’s sperm inherited the altered TP53 gene. Only those who received a sperm cell carrying the mutation were affected. That explains why some of the nearly 200 children appear healthy so far, while a smaller number have developed serious illnesses.
How sperm donors are usually screened
Sperm banks in Europe, North America and elsewhere generally claim to apply strict checks on donors. These typically include:
- extensive medical and family history questionnaires
- blood and urine tests for infectious diseases such as HIV and hepatitis
- basic genetic screening for well‑known disorders, for example cystic fibrosis
- semen analysis to assess sperm count and quality
Advanced screening for hundreds of rare mutations is not yet standard everywhere, partly due to cost, and partly because interpreting rare variants remains technically and ethically complex.
This case exposes a clear limitation: mosaic mutations confined to reproductive cells can slip through conventional testing, particularly when the donor shows no symptoms and has no known family history of cancer.
Numbers at a glance
| Period of donations | 2006–2022 |
|---|---|
| Number of children conceived | 197 |
| Countries involved | 14 |
| Clinics supplied | 67 |
| Gene affected | TP53 (rare mutation) |
Global implications for fertility clinics
The scandal reaches far beyond Denmark. Because the donor’s sperm was exported widely, clinics in more than a dozen countries have had to review patient records, contact families and assess who might be at risk.
For parents, the emotional impact can be immense. Many went through years of fertility struggles before finally having a child. Now they must weigh up genetic testing for their children, monitor for early warning signs of illness and deal with uncertainty about future health.
The case forces sperm banks to question how many children a single donor should be allowed to father and how deeply they should be screened.
Some specialists argue for tighter international caps on the number of pregnancies per donor, to limit the potential impact of any undiscovered mutation. Others call for broader genetic panels and specific tests aimed at detecting mosaicism in sperm samples.
What parents using donor sperm can do
Parents who have used donor sperm, especially from international banks, may now feel anxious, even if they are not directly linked to this specific donor. While the absolute risk of a similar scenario is low, there are practical steps any concerned family can take.
- Check documentation provided by the fertility clinic, including donor ID numbers.
- Ask the clinic whether any safety alerts have been issued about the donor used.
- Discuss with a genetic counsellor if your child has a donor background and unexplained health issues.
- Consider genetic testing when recommended by a specialist, particularly if there is an early cancer diagnosis.
Genetic counselling can help families understand complex results, the difference between a variant of unknown significance and a clearly harmful mutation, and what level of monitoring might be sensible.
Key genetic concepts behind the story
Several technical terms sit at the heart of this case. Understanding them makes the stakes clearer.
Mosaicism
Mosaicism occurs when not all cells in a person’s body share the same DNA. A mutation may arise during early development or later in life, so only a proportion of cells carry it.
If the mutation is present only in reproductive cells, such as sperm, the individual can be perfectly healthy, yet still pass the mutation to some offspring. This seems to be what happened with the Danish donor and the TP53 variant.
Penetrance and risk
Even when someone inherits a cancer‑linked mutation, disease is not guaranteed. Geneticists talk about “penetrance”: the probability that a person carrying a mutation will actually develop the associated condition.
For high‑risk genes like TP53, penetrance can be substantial, especially during childhood or early adulthood. That is why early surveillance is often recommended when such a mutation is confirmed.
What this case signals for the future of donor screening
The Danish incident is likely to accelerate discussions around how deeply donors should be genetically tested. Large, multi‑gene panels could catch more inherited disorders, but they also raise difficult questions.
Who pays for extensive screening? How are rare, poorly understood variants handled? At what point does excluding donors for uncertain results reduce the donor pool so sharply that access to fertility treatment suffers?
Some experts suggest targeted strategies: more detailed sequencing of the sperm itself for donors who father large numbers of children, closer tracking of medical outcomes in donor‑conceived offspring, and clear international reporting systems for suspected genetic problems.
For families relying on donor conception, the case highlights a difficult balance. Modern reproductive medicine can open paths to parenthood that would once have been closed. At the same time, genetic risks, even very rare ones, cannot be reduced to zero, and transparent handling of such incidents will play a growing role in maintaining trust.
Originally posted 2026-03-12 23:40:44.